_id
691b209e3c536f8df2318d95
Ticker
NWRN.SW
Name
Newron Pharmaceuticals SpA
Exchange
SW
Address
Via Antonio Meucci 3, Bresso, MI, Italy, 20091
Country
Switzerland
Sector
Healthcare
Industry
Biotechnology
Currency
CHF
Website
https://www.newron.com
Description
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Last Close
24.45
Volume
106894
Current Price
30.85
Change
-0.6
Last Updated
2026-01-01T00:11:02.375Z
Image
https://logo.clearbit.com/www.newron.com
Ipo Date
-
Market Cap
476069728
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
11898000
Cost Of Revenue
-
Gross Profit
11898000
Operating Expenses
10553000
Operating Income
1345000
Interest Expense
1927000
Pretax Income
-57000
Net Income
-73000
Eps
-0.003657314629258517
Dividends Per Share
-
Shares Outstanding
19960994
Income Tax Expense
16000
EBITDA
1430000
Operating Margin
11.304420911077493
Total Other Income Expense Net
-1402000
Cash
26639000
Short Term Investments
16556000
Receivables
8240000
Inventories
-
Total Current Assets
60468000
Property Plant Equipment
780000
Total Assets
61394000
Payables
1090000
Short Term Debt
33897000
Long Term Debt
18055000
Total Liabilities
59812000
Equity
1582000
Bs_currency_symbol
EUR
Depreciation
85000
Change In Working Capital
35801000
Cash From Operations
33353000
Capital Expenditures
31000
Cash From Investing
-13553000
Cash From Financing
-94000
Net Change In Cash
26639000
Cf_currency_symbol
-
PE
18.9286
PB
389.2326169405816
ROE
-4.61441213653603
ROA
-0.11890412743916343
FCF
33322000
Fcf Percent
2.80063876281728
Piotroski FScore
2
Health Score
28
Deep Value Investing Score
4
Defensive Investing Score
5.5
Dividend Investing Score
3
Economic Moat Investing Score
5.8
Garp Investing Score
2.5
Growth Investing Score
3
Momentum Investing Score
6.5
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
3.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
11898000
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
11898000
Quarters > 0 > income Statement > operating Expenses
10553000
Quarters > 0 > income Statement > operating Income
1345000
Quarters > 0 > income Statement > interest Expense
1927000
Quarters > 0 > income Statement > pretax Income
-57000
Quarters > 0 > income Statement > net Income
-73000
Quarters > 0 > income Statement > eps
-0.003657314629258517
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
19960000
Quarters > 0 > income Statement > income Tax Expense
16000
Quarters > 0 > income Statement > EBITDA
1430000
Quarters > 0 > income Statement > operating Margin
11.304420911077493
Quarters > 0 > income Statement > total Other Income Expense Net
-1402000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
26639000
Quarters > 0 > balance Sheet > short Term Investments
16556000
Quarters > 0 > balance Sheet > receivables
8240000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
60468000
Quarters > 0 > balance Sheet > property Plant Equipment
780000
Quarters > 0 > balance Sheet > total Assets
61394000
Quarters > 0 > balance Sheet > payables
1090000
Quarters > 0 > balance Sheet > short Term Debt
33897000
Quarters > 0 > balance Sheet > long Term Debt
18055000
Quarters > 0 > balance Sheet > total Liabilities
59812000
Quarters > 0 > balance Sheet > equity
1582000
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
-73000
Quarters > 0 > cash Flow > depreciation
85000
Quarters > 0 > cash Flow > change In Working Capital
35801000
Quarters > 0 > cash Flow > cash From Operations
33353000
Quarters > 0 > cash Flow > capital Expenditures
31000
Quarters > 0 > cash Flow > cash From Investing
-13553000
Quarters > 0 > cash Flow > cash From Financing
-94000
Quarters > 0 > cash Flow > net Change In Cash
26639000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.003657314629258517
Quarters > 0 > ratios > PB
389.2326169405816
Quarters > 0 > ratios > ROE
-4.61441213653603
Quarters > 0 > ratios > ROA
-0.11890412743916343
Quarters > 0 > ratios > FCF
33322000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
2.80063876281728
Quarters > 0 > health Score
28
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
47983000
Quarters > 1 > income Statement > cost Of Revenue
718000
Quarters > 1 > income Statement > gross Profit
47983000
Quarters > 1 > income Statement > operating Expenses
14127000
Quarters > 1 > income Statement > operating Income
33856000
Quarters > 1 > income Statement > interest Expense
4353000
Quarters > 1 > income Statement > pretax Income
30938000
Quarters > 1 > income Statement > net Income
25400000
Quarters > 1 > income Statement > eps
1.368313311425955
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
18563000
Quarters > 1 > income Statement > income Tax Expense
5538000
Quarters > 1 > income Statement > EBITDA
33526000
Quarters > 1 > income Statement > operating Margin
70.5583227393035
Quarters > 1 > income Statement > total Other Income Expense Net
-2918000
Quarters > 1 > income Statement > currency_symbol
CHF
Quarters > 1 > balance Sheet > cash
6933000
Quarters > 1 > balance Sheet > short Term Investments
2893000
Quarters > 1 > balance Sheet > receivables
42423000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
61104000
Quarters > 1 > balance Sheet > property Plant Equipment
834000
Quarters > 1 > balance Sheet > total Assets
63908000
Quarters > 1 > balance Sheet > payables
2465000
Quarters > 1 > balance Sheet > short Term Debt
13553000
Quarters > 1 > balance Sheet > long Term Debt
36243000
Quarters > 1 > balance Sheet > total Liabilities
62450000
Quarters > 1 > balance Sheet > equity
1458000
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
30951000
Quarters > 1 > cash Flow > depreciation
96000
Quarters > 1 > cash Flow > change In Working Capital
-38221000
Quarters > 1 > cash Flow > cash From Operations
-8786000
Quarters > 1 > cash Flow > capital Expenditures
6000
Quarters > 1 > cash Flow > cash From Investing
1149000
Quarters > 1 > cash Flow > cash From Financing
6673000
Quarters > 1 > cash Flow > net Change In Cash
-964000
Quarters > 1 > cash Flow > currency_symbol
CHF
Quarters > 1 > ratios > PE
1.368313311425955
Quarters > 1 > ratios > PB
392.77678326474626
Quarters > 1 > ratios > ROE
1742.1124828532236
Quarters > 1 > ratios > ROA
39.74463290980785
Quarters > 1 > ratios > FCF
-8792000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
-0.18323156117791717
Quarters > 1 > health Score
48
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
3407000
Quarters > 2 > income Statement > cost Of Revenue
174000
Quarters > 2 > income Statement > gross Profit
3407000
Quarters > 2 > income Statement > operating Expenses
11090000
Quarters > 2 > income Statement > operating Income
-7683000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-9544000
Quarters > 2 > income Statement > net Income
-9557000
Quarters > 2 > income Statement > eps
-0.5148413510747185
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
18563000
Quarters > 2 > income Statement > income Tax Expense
13000
Quarters > 2 > income Statement > EBITDA
-7587000
Quarters > 2 > income Statement > operating Margin
-225.50631053712942
Quarters > 2 > income Statement > total Other Income Expense Net
-1861000
Quarters > 2 > income Statement > currency_symbol
CHF
Quarters > 2 > balance Sheet > cash
7897000
Quarters > 2 > balance Sheet > short Term Investments
4291000
Quarters > 2 > balance Sheet > receivables
2512000
Quarters > 2 > balance Sheet > inventories
2449000
Quarters > 2 > balance Sheet > total Current Assets
20080000
Quarters > 2 > balance Sheet > property Plant Equipment
342000
Quarters > 2 > balance Sheet > total Assets
24937000
Quarters > 2 > balance Sheet > payables
2868000
Quarters > 2 > balance Sheet > short Term Debt
184000
Quarters > 2 > balance Sheet > long Term Debt
48530000
Quarters > 2 > balance Sheet > total Liabilities
55769000
Quarters > 2 > balance Sheet > equity
-30832000
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
-9557000
Quarters > 2 > cash Flow > depreciation
96000
Quarters > 2 > cash Flow > change In Working Capital
468000
Quarters > 2 > cash Flow > cash From Operations
-8828000
Quarters > 2 > cash Flow > capital Expenditures
7000
Quarters > 2 > cash Flow > cash From Investing
2009000
Quarters > 2 > cash Flow > cash From Financing
8378000
Quarters > 2 > cash Flow > net Change In Cash
7897000
Quarters > 2 > cash Flow > currency_symbol
CHF
Quarters > 2 > ratios > PE
-0.5148413510747185
Quarters > 2 > ratios > PB
-18.573837247016087
Quarters > 2 > ratios > ROE
30.99701608718215
Quarters > 2 > ratios > ROA
-38.32457793639973
Quarters > 2 > ratios > FCF
-8835000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-2.5931904901673026
Quarters > 2 > health Score
31
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
3563000
Quarters > 3 > income Statement > cost Of Revenue
288000
Quarters > 3 > income Statement > gross Profit
3563000
Quarters > 3 > income Statement > operating Expenses
10886000
Quarters > 3 > income Statement > operating Income
-7323000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-9261000
Quarters > 3 > income Statement > net Income
-9274000
Quarters > 3 > income Statement > eps
-0.519697394228075
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
17845000
Quarters > 3 > income Statement > income Tax Expense
13000
Quarters > 3 > income Statement > EBITDA
-7288000
Quarters > 3 > income Statement > operating Margin
-205.52904855458883
Quarters > 3 > income Statement > total Other Income Expense Net
-1938000
Quarters > 3 > income Statement > currency_symbol
CHF
Quarters > 3 > balance Sheet > cash
6338000
Quarters > 3 > balance Sheet > short Term Investments
6261000
Quarters > 3 > balance Sheet > receivables
2022000
Quarters > 3 > balance Sheet > inventories
1
Quarters > 3 > balance Sheet > total Current Assets
19652000
Quarters > 3 > balance Sheet > property Plant Equipment
405000
Quarters > 3 > balance Sheet > total Assets
25866000
Quarters > 3 > balance Sheet > payables
2019000
Quarters > 3 > balance Sheet > short Term Debt
22452000
Quarters > 3 > balance Sheet > long Term Debt
25753000
Quarters > 3 > balance Sheet > total Liabilities
55774000
Quarters > 3 > balance Sheet > equity
-29908000
Quarters > 3 > balance Sheet > currency_symbol
EUR
Quarters > 3 > cash Flow > net Income
-9274000
Quarters > 3 > cash Flow > depreciation
99000
Quarters > 3 > cash Flow > change In Working Capital
958000
Quarters > 3 > cash Flow > cash From Operations
-4537000
Quarters > 3 > cash Flow > capital Expenditures
3000
Quarters > 3 > cash Flow > cash From Investing
3257000
Quarters > 3 > cash Flow > cash From Financing
-95000
Quarters > 3 > cash Flow > net Change In Cash
-7713000
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
-0.519697394228075
Quarters > 3 > ratios > PB
-18.407056640363784
Quarters > 3 > ratios > ROE
31.00842583924034
Quarters > 3 > ratios > ROA
-35.854016856104536
Quarters > 3 > ratios > FCF
-4540000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-1.2742071288240246
Quarters > 3 > health Score
31
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
51390000
Annuals > 0 > income Statement > cost Of Revenue
892000
Annuals > 0 > income Statement > gross Profit
51390000
Annuals > 0 > income Statement > operating Expenses
25217000
Annuals > 0 > income Statement > operating Income
26173000
Annuals > 0 > income Statement > interest Expense
4353000
Annuals > 0 > income Statement > pretax Income
21394000
Annuals > 0 > income Statement > net Income
15843000
Annuals > 0 > income Statement > eps
0.8534719603512363
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
18563000
Annuals > 0 > income Statement > income Tax Expense
5551000
Annuals > 0 > income Statement > EBITDA
25939000
Annuals > 0 > income Statement > operating Margin
50.93014205098269
Annuals > 0 > income Statement > total Other Income Expense Net
-4779000
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
6933000
Annuals > 0 > balance Sheet > short Term Investments
2893000
Annuals > 0 > balance Sheet > receivables
42423000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
61104000
Annuals > 0 > balance Sheet > property Plant Equipment
834000
Annuals > 0 > balance Sheet > total Assets
63908000
Annuals > 0 > balance Sheet > payables
2465000
Annuals > 0 > balance Sheet > short Term Debt
13553000
Annuals > 0 > balance Sheet > long Term Debt
36243000
Annuals > 0 > balance Sheet > total Liabilities
62450000
Annuals > 0 > balance Sheet > equity
1458000
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
21394000
Annuals > 0 > cash Flow > depreciation
192000
Annuals > 0 > cash Flow > change In Working Capital
-37753000
Annuals > 0 > cash Flow > cash From Operations
-17614000
Annuals > 0 > cash Flow > capital Expenditures
13000
Annuals > 0 > cash Flow > cash From Investing
3158000
Annuals > 0 > cash Flow > cash From Financing
15051000
Annuals > 0 > cash Flow > net Change In Cash
595000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
0.8534719603512363
Annuals > 0 > ratios > PB
303.654012345679
Annuals > 0 > ratios > ROE
1086.625514403292
Annuals > 0 > ratios > ROA
24.790323590160856
Annuals > 0 > ratios > FCF
-17627000
Annuals > 0 > ratios > Piotroski FScore
2
Annuals > 0 > ratios > fcf Percent
-0.3430044755789064
Annuals > 0 > health Score
48
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
9057000
Annuals > 1 > income Statement > cost Of Revenue
471000
Annuals > 1 > income Statement > gross Profit
9057000
Annuals > 1 > income Statement > operating Expenses
20686000
Annuals > 1 > income Statement > operating Income
-11629000
Annuals > 1 > income Statement > interest Expense
4168000
Annuals > 1 > income Statement > pretax Income
-16200000
Annuals > 1 > income Statement > net Income
-16224000
Annuals > 1 > income Statement > eps
-0.9091622303166152
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
17845000
Annuals > 1 > income Statement > income Tax Expense
24000
Annuals > 1 > income Statement > EBITDA
-11831000
Annuals > 1 > income Statement > operating Margin
-128.3979242574804
Annuals > 1 > income Statement > total Other Income Expense Net
-4571000
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
6338000
Annuals > 1 > balance Sheet > short Term Investments
6261000
Annuals > 1 > balance Sheet > receivables
2530000
Annuals > 1 > balance Sheet > inventories
-508001
Annuals > 1 > balance Sheet > total Current Assets
19652000
Annuals > 1 > balance Sheet > property Plant Equipment
405000
Annuals > 1 > balance Sheet > total Assets
25866000
Annuals > 1 > balance Sheet > payables
2019000
Annuals > 1 > balance Sheet > short Term Debt
22452000
Annuals > 1 > balance Sheet > long Term Debt
25753000
Annuals > 1 > balance Sheet > total Liabilities
55774000
Annuals > 1 > balance Sheet > equity
-29908000
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
-16200000
Annuals > 1 > cash Flow > depreciation
201000
Annuals > 1 > cash Flow > change In Working Capital
1636000
Annuals > 1 > cash Flow > cash From Operations
-10140000
Annuals > 1 > cash Flow > capital Expenditures
11000
Annuals > 1 > cash Flow > cash From Investing
3246000
Annuals > 1 > cash Flow > cash From Financing
-192000
Annuals > 1 > cash Flow > net Change In Cash
-7086000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-0.9091622303166152
Annuals > 1 > ratios > PB
-14.230414939146717
Annuals > 1 > ratios > ROE
54.24635549016985
Annuals > 1 > ratios > ROA
-62.723266063558334
Annuals > 1 > ratios > FCF
-10151000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-1.1207905487468257
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
6094000
Annuals > 2 > income Statement > cost Of Revenue
443000
Annuals > 2 > income Statement > gross Profit
6094000
Annuals > 2 > income Statement > operating Expenses
19396000
Annuals > 2 > income Statement > operating Income
-13302000
Annuals > 2 > income Statement > interest Expense
4363296
Annuals > 2 > income Statement > pretax Income
-17472000
Annuals > 2 > income Statement > net Income
-17493000
Annuals > 2 > income Statement > eps
-0.9802745867189689
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
17845000
Annuals > 2 > income Statement > income Tax Expense
21000
Annuals > 2 > income Statement > EBITDA
-13323000
Annuals > 2 > income Statement > operating Margin
-218.2802756809977
Annuals > 2 > income Statement > total Other Income Expense Net
-4170000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
13424000
Annuals > 2 > balance Sheet > short Term Investments
9350000
Annuals > 2 > balance Sheet > receivables
1944000
Annuals > 2 > balance Sheet > inventories
1
Annuals > 2 > balance Sheet > total Current Assets
28493000
Annuals > 2 > balance Sheet > property Plant Equipment
527000
Annuals > 2 > balance Sheet > total Assets
37195000
Annuals > 2 > balance Sheet > payables
1909000
Annuals > 2 > balance Sheet > short Term Debt
172000
Annuals > 2 > balance Sheet > long Term Debt
45165000
Annuals > 2 > balance Sheet > total Liabilities
51225000
Annuals > 2 > balance Sheet > equity
-14030000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
-17493000
Annuals > 2 > cash Flow > depreciation
202000
Annuals > 2 > cash Flow > change In Working Capital
1308000
Annuals > 2 > cash Flow > cash From Operations
-11092000
Annuals > 2 > cash Flow > capital Expenditures
18000
Annuals > 2 > cash Flow > cash From Investing
-317000
Annuals > 2 > cash Flow > cash From Financing
-186000
Annuals > 2 > cash Flow > net Change In Cash
-11595000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-0.9802745867189689
Annuals > 2 > ratios > PB
-30.335228082679972
Annuals > 2 > ratios > ROE
124.68282252316465
Annuals > 2 > ratios > ROA
-47.030514854147064
Annuals > 2 > ratios > FCF
-11110000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-1.8231046931407942
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
5762000
Annuals > 3 > income Statement > cost Of Revenue
117000
Annuals > 3 > income Statement > gross Profit
5762000
Annuals > 3 > income Statement > operating Expenses
18119000
Annuals > 3 > income Statement > operating Income
-12357000
Annuals > 3 > income Statement > interest Expense
2918000
Annuals > 3 > income Statement > pretax Income
-14884000
Annuals > 3 > income Statement > net Income
-14901000
Annuals > 3 > income Statement > eps
-0.8350238161950126
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
17845000
Annuals > 3 > income Statement > income Tax Expense
17000
Annuals > 3 > income Statement > EBITDA
-11919000
Annuals > 3 > income Statement > operating Margin
-214.4567858382506
Annuals > 3 > income Statement > total Other Income Expense Net
-2527000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
25019000
Annuals > 3 > balance Sheet > short Term Investments
9575000
Annuals > 3 > balance Sheet > receivables
1308000
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
39427000
Annuals > 3 > balance Sheet > property Plant Equipment
577000
Annuals > 3 > balance Sheet > total Assets
50486000
Annuals > 3 > balance Sheet > payables
1503000
Annuals > 3 > balance Sheet > short Term Debt
150000
Annuals > 3 > balance Sheet > long Term Debt
42542000
Annuals > 3 > balance Sheet > total Liabilities
47379000
Annuals > 3 > balance Sheet > equity
3107000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
-14901000
Annuals > 3 > cash Flow > depreciation
209000
Annuals > 3 > cash Flow > change In Working Capital
3683000
Annuals > 3 > cash Flow > cash From Operations
-11445000
Annuals > 3 > cash Flow > capital Expenditures
20000
Annuals > 3 > cash Flow > cash From Investing
8420000
Annuals > 3 > cash Flow > cash From Financing
14831000
Annuals > 3 > cash Flow > net Change In Cash
11806000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-0.8350238161950126
Annuals > 3 > ratios > PB
136.98205664628262
Annuals > 3 > ratios > ROE
-479.5944641132926
Annuals > 3 > ratios > ROA
-29.515113100661573
Annuals > 3 > ratios > FCF
-11465000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-1.989760499826449
Annuals > 3 > health Score
8
Valuation > metrics > PE
18.9286
Valuation > metrics > PB
389.2326169405816
Valuation > final Score
50
Valuation > verdict
6437.2% Overvalued
Profitability > metrics > ROE
-4.61441213653603
Profitability > metrics > ROA
-0.12072501157637099
Profitability > metrics > Net Margin
-0.006135484955454698
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
37.80783817951959
Risk > metrics > Interest Coverage
0.6979761286974572
Risk > final Score
9
Risk > verdict
High
Liquidity > metrics > Current Ratio
1.7282990825163633
Liquidity > metrics > Quick Ratio
1.7282990825163633
Liquidity > final Score
93
Liquidity > verdict
Great
Prev Valuations > 0
40
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
100
Prev Profitabilities > 1
40
Prev Profitabilities > 2
40
Prev Risks > 0
37
Prev Risks > 1
14
Prev Risks > 2
15
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
50
Updated At
2026-01-20T23:11:31.160Z
Earnings History > 0 > period
2025-06-30
Earnings History > 0 > report Date
2025-09-16
Earnings History > 0 > date
2025-06-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
-0.5
Earnings History > 0 > eps Difference
0.5
Earnings History > 0 > surprise Percent
100
Earnings History > 1 > period
2024-12-31
Earnings History > 1 > report Date
2025-03-31
Earnings History > 1 > date
2024-12-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
1.12
Earnings History > 1 > eps Estimate
-0.49
Earnings History > 1 > eps Difference
1.61
Earnings History > 1 > surprise Percent
328.5714
Earnings History > 2 > period
2022-06-30
Earnings History > 2 > report Date
2022-09-15
Earnings History > 2 > date
2022-06-30
Earnings History > 2 > before After Market
AfterMarket
Earnings History > 2 > currency
EUR
Earnings History > 2 > eps Actual
0
Earnings History > 2 > eps Estimate
-0.44
Earnings History > 2 > eps Difference
0.44
Earnings History > 2 > surprise Percent
100
Earnings History > 3 > period
2017-12-31
Earnings History > 3 > report Date
2018-03-01
Earnings History > 3 > date
2017-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
EUR
Earnings History > 3 > eps Actual
-0.41
Earnings History > 3 > eps Estimate
-1
Earnings History > 3 > eps Difference
0.59
Earnings History > 3 > surprise Percent
59
Earnings History > 4 > period
2017-06-30
Earnings History > 4 > report Date
2017-09-14
Earnings History > 4 > date
2017-06-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
EUR
Earnings History > 4 > eps Actual
0.09
Earnings History > 4 > eps Estimate
-0.35
Earnings History > 4 > eps Difference
0.44
Earnings History > 4 > surprise Percent
125.7143
Earnings History > 5 > period
2016-12-31
Earnings History > 5 > report Date
2017-03-02
Earnings History > 5 > date
2016-12-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
EUR
Earnings History > 5 > eps Actual
-0.41
Earnings History > 5 > eps Estimate
-1.12
Earnings History > 5 > eps Difference
0.71
Earnings History > 5 > surprise Percent
63.3929
Earnings History > 6 > period
2016-06-30
Earnings History > 6 > report Date
2016-09-15
Earnings History > 6 > date
2016-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
EUR
Earnings History > 6 > eps Actual
-0.64
Earnings History > 6 > eps Estimate
-0.74
Earnings History > 6 > eps Difference
0.1
Earnings History > 6 > surprise Percent
13.5135
Earnings History > 7 > period
2015-12-31
Earnings History > 7 > report Date
2016-03-22
Earnings History > 7 > date
2015-12-31
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
EUR
Earnings History > 7 > eps Actual
-1.13
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
-1.13
Earnings History > 7 > surprise Percent
-
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Stock Price
CHF0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ANWRN.SW Newron Pharmaceuticals (SIX) pre-market 16 Jan: -5.42%, earnings watch Meyka
Read more →3 European Growth Companies With Up To 33% Insider Ownership Yahoo Finance
Read more →Showing 2 of 6
(Last Updated 2025-06-30)
Rating:
BUY
$
Analyst Picks
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-06-30)
Health Score
Price to Earnings Ratio (P/E)
-
High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Newron Pharmaceuticals SpA
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-06-30
EPS Actual
0
EPS Estimate
-0.5
EPS Difference
0.5
Surprise Percent
100%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
CHF 0
Cost Of Revenue
CHF 0
Gross Profit
CHF 0
Operating Expenses
CHF 0
Operating Income
CHF 0
Interest Expense
CHF 0
Pretax Income
CHF 0
Net Income
CHF 0
Income Tax Expense
CHF 0
EBITDA
CHF 0
Total Other Income Expense Net
CHF 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
CHF 0
Short Term Investments
CHF 0
Receivables
CHF 0
Inventories
CHF 0
Total Current Assets
CHF 0
Property Plant Equipment
CHF 0
Total Assets
CHF 0
Payables
CHF 0
Short Term Debt
CHF 0
Long Term Debt
CHF 0
Total Liabilities
CHF 0
Equity
CHF 0
(Last Updated 2025-06-30)
Net Income
CHF 0
Depreciation
CHF 0
Change In Working Capital
CHF 0
Cash From Operations
CHF 0
Capital Expenditures
CHF 0
Cash From Investing
CHF 0
Cash From Financing
CHF 0
Net Change In Cash
CHF 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.